Actinogen Medical Limited · ASX:ACW
Actinogen Medical — ShareCafe Small Cap Hidden Gems investor webinar (October 2022)
20 slides from Actinogen Medical's conference presentation, Oct 21, 2022
Slide 1: Actinogen CEO presentation to ShareCafe investor webinar
For personal use only ASX ANNOUNCEMENT Actinogen CEO presentation to ShareCafe investor webinar Sydney, 21 October 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce its participation in the ShareCafe Small Cap Hidden Gems investor webinar, to be held today from 12:30pm
Slide 2: About Actinogen Medical
About Actinogen Medical Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affectin
Slide 3: New Alzheimer's Disease Phase 2a trial results show strong clinical effect
For personal use only New Alzheimer’s Disease Phase 2a trial results show strong clinical effect Major validation of ‘cortisol hypothesis’ Dr. Steven Gourlay MBBS PhD MBA, CEO & MD Presented at Sharecafe Hidden Gems webinar 21 October 2022 Authorised by the Board of Directors of Actinogen Medical Li
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Actinogen Medical Limited. (“Actinogen” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all inform
Slide 5: ACW top stockholders and stock price
ACW top stockholders and stock price For personal use only Share price chart at 19 October 2022 Trading Information 52 week high A$0.20 52 week low A$0.04 25.0m Number of issued shares 1,796M 0.19 Market capitalisation (19 Oct 2022) A$216M 0.17 20.0m Cash Balance at 30 Jun 2022 A$20M1 0.15 Share pri
Slide 6: Leadership and Management
Leadership and Management Extensive drug development and commercial experience For personal use only Experienced Board of Directors... …with a talented management team in place Jeff Carter Chief Financial Officer B. Fin Admin; M. App. Fin; CA Tamara Miller SVP Product Development M.Med Sci; BSc; MSc
Slide 7: Xanamem: Oral, low dose, once-a-day treatment with a unique non-amyloid mechanism
Xanamem: Oral, low dose, once-a-day treatment with a unique non-amyloid mechanism For personal use only Brain penetrant 11β-HSD1 small molecule enzyme inhibitor reduces cortisol inside brain cells - modulating signaling pathways and underlying disease processes1,2 Potential to be: • Rapidly cognitiv
Slide 8: ACW Xanamem program – current status
ACW Xanamem program – current status For personal use only 300 people safely tested in trials using Xanamem Positive attention and memory (cognition) results in two trials Last week – large therapeutic effect in early-stage Alzheimer’s Disease (AD) patients FDA approved endpoints Commencing
Slide 9: Xanamem doubled rate of disease stabilization
Xanamem doubled rate of disease stabilization Response analysis in Alzheimer’s Disease patients:1 For personal use only • Twice as many patients in the Xanamem group had stable or improved disease compared with placebo2 • 56% of patients treated with Xanamem were stable or improved • 60-80% relative
Slide 10: Data shows large Xanamem clinical effect in AD patients
Data shows large Xanamem clinical effect in AD patients Biomarker-positive patients likely to progress to more severe disease For personal use only N Clinical Dementia Rating – Sum of Boxes (CDR-SB)1 Elevated pTau Group Desired Xanamem Placebo Cohen’s p value change d pTau >6.74 pg/mL1 (mean) 34 Dow
Slide 11: The Xanamem opportunity in Depression
The Xanamem opportunity in Depression For personal use only Current anti-depressants work slowly (3 weeks) and do not target cognition multiple adverse effects initial suicide risk blood pressure, sexual function, appetite… Xanamem improves cognition quickly Xanamem may improve both depression and c
Slide 12: Xanamem Phase & program
Xanamem Phase 2 & 3 program Building on four independent Phase 1 and 2 studies showing activity For personal use only Current Phase 1 & 2a, biomarker Safety, cognition activity (n~300) Phase 2b Phase 2a Cognitive Impairment Alzheimer’s Disease (AD) in Depressive Disorder (CIDD) Phase 3 Phase 3 Alzhe
Slide 13: Actinogen strategy validated by new results
Actinogen strategy validated by new results Backed by strong balance sheet and intellectual property For personal use only Accelerate clinical development Create value from partnerships • Focus on cognitive enhancement: Pharma/biotech engagement • Patients with early Alzheimer’s Disease • Actively e
Slide 14: Xanamem timeline & catalysts
Xanamem timeline & catalysts For personal use only • October multiple partnering presentations of new results • November CTAD1 XanaMIA presentation • Trial enrollment starts for XanaCIDD trial in Depression 2022 • Key global regulatory submissions in AD with FDA, EMA, other • Phase 2b XanaMIA AD tri
Slide 15: Questions
For personal use only Questions Sharecafe Hidden Gems webinar 21 Oct 2022 13
Slide 16: Thank you
For personal use only Thank you If you have any questions following the webinar please contact: Dr. Steven Gourlay Michael Roberts CEO & Managing Director Investor Relations P. +61 2 8964 7401 M. +61 423 866 231 E. steven.gourlay@actinogen.com.au E. michael.roberts@actinogen.com.au Sharecafe Hidden
Slide 17: Appendix
For personal use only Appendix Sharecafe Hidden Gems webinar 21 Oct 2022 15
Slide 18: Actinogen company snapshot
Actinogen company snapshot Actinogen Medical (ASX:ACW) is developing a novel oral treatment with rapid onset of For personal use only clinical activity to improve cognition and quality of life Demonstrated target engagement in brain and HPA axis1 in human trials Favourable pharmaceutical propertie
Slide 19: Selected glossary
Selected glossary 1 For personal use only 11β-HSD1 11 beta HydroxySteroid Dehydrogenase-1 enzyme Aβ Amyloid beta – a type of amyloid protein associated with Alzheimer’s Disease, 42 and 40 are different forms ACTH Adrenocorticotropic hormone that regulates blood levels of cortisol ADAS-Cog Alzheimer’
Slide 20: Selected glossary
Selected glossary 2 For personal use only IQCODE Informant Questionnaire on Cognitive Decline in the Elderly MCI Mild Cognitive Impairment – memory, executive function deterioration with retained functional abilities MDD Major Depressive Disorder MMSE Mini Mental State Examination – a 30-point scale
Actinogen Medical — ShareCafe Small Cap Hidden Gems investor webinar (October 2022) on 6ix